Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dacomitinib Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 8/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacomitinib Anhydrous SCHEMBL29354322 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL30115337 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29377735 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL25637 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29396914 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL25098 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL33136 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL22498351 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29445648 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| Dacomitinib Anhydrous SCHEMBL29359689 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724150-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724151-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2025122699-A1 | CDC7 INHIBITOR COMBINATIONAL THERAPY | Lin Bioscience, Inc. (TW) | 2025-06-12 | — | — | WO | claimed |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2025-04-15 | — | — | US | claimed |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | Lin Bioscience, Inc. (TW) | 2025-03-20 | — | — | US | claimed |
| WO-2024254298-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024254266-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| WO-2022098992-A1 | USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| WO-2022094271-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022072632-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022072645-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| CN-113717111-A | Crystal form of quinazoline compound and preparation method thereof | 苏州晶云药物科技股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-112955137-A | Combination therapy | 米拉蒂治疗股份有限公司 | 2021-06-11 | — | — | CN | claimed |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | BTK, LCK, DSTYK | EGFR 228/4885ERBB2 52/4885ERBB4 349/4885 |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | CDC7, MCM7, BOD1L1 | EGFR 3296/4885ERBB2 2597/4885ERBB4 2324/4885 |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | EGFR 842/4885ERBB2 1158/4885ERBB4 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.